Clinical trial

Determining to the Effect of Pectointercostal and ESP Block on Postoperative Analgesia During Open Heart Surgery

Name
Pectointercostal and ESP block
Description
American Society of Anaesthesiologist physical status II-III, aged between 18-65, 60 patients which underwent open cardiac surgery will recruited to this study. These subjects will Ultrasound (USG) guided erector spinae block will perform at T6 level (bilaterally) and pectointercostal plane block at 4-5 intercostal space to the all patient under general anaesthesia. Totally bupivacaine %0.25 2.5 mg/kg will use blocks and 1 ml epinephrin will add to the each local anesthetic solutions. 10 ml %0.25 bupivacain will apply to the chest tube area at the end of surgery. 0.1 microgram/kg morphine will apply intravenously at last 30 minutes of surgery postoperative analgesia to all patients. Postoperative pain assessment will perform with visual analog scale (VAS)
Trial arms
Trial start
2022-11-15
Estimated PCD
2023-08-15
Trial end
2023-08-15
Status
Recruiting
Phase
Early phase I
Treatment
Pectointercostal and ESP block
Pectointercostal plane block will apply at the 4-5. intercostal space and ESP block will apply athe T6 level bilaterally
Arms:
Control Group, Pectointercostal and ESP
Other names:
Fascial plane blocks
Size
60
Primary endpoint
Postoperative analgesia
24 hours in Postanesthesia care unit (PACU)
Morphine consumption
24 hours in Postanesthesia care unit (PACU)
Eligibility criteria
Inclusion Criteria: * ASA II-III patients * The patients who will operate for open heart surgery Exclusion Criteria: * The patients with Coagulopaty * Allergy with local anesthetics * infection at the injection sites * Obesity (BMI \>35kg/m2) * Liver and/or kidney failure
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 60, 'type': 'ESTIMATED'}}
Updated at
2023-04-27

1 organization

1 product

1 indication